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Disulﬁde bridgea b s t r a c t
Membrane attachment of prion protein (PrP) via its glycosylphosphatidylinositol (GPI) anchor plays
a key role during conversion of cellular PrPC into its pathogenic isoform PrPSc. Strategies to access
homogenous lipidated PrP via expressed protein ligation (EPL) are required to fully decipher the
effect of membrane attachment. Such strategies suffer from insoluble expression of PrP-intein
fusion constructs and low folding efﬁciencies that severely limit the available amount of homoge-
neous lipidated PrP. Here, we describe an alternative method for expression of soluble PrP-intein
fusion proteins in Escherichia coli that provides access to natively folded PrP ready to use in EPL.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction when both protein variants are inserted into contiguous mem-Prion diseases or transmissible spongiform encephalopathies
(TSEs) are infectious neurodegenerative disorders (e.g. scrapie in
sheep, BSE in cattle and CJD in humans), which are caused by con-
version of cellular, predominantly a-helical prion protein (PrPC)
into a toxic, b-sheet-rich isoform (PrPSc) [1–5]. Typically, PrPC can
be found anchored to the outer leaﬂet of cell membranes via its
C-terminally attached glycosylphosphatidylinositol (GPI) anchor.
The biological function of PrPC itself and its attachment to cellular
membranes is not yet fully understood. However, membrane
attachment of PrPC, especially the preference for ordered mem-
brane domains, plays an important role in converting PrPC to PrPSc
and strategies to generate homogeneous membrane-anchored PrP
variants by expressed protein ligation have been developed [6,7].
This ﬁnding is supported by the fact that both PrPC and PrPSc were
found in ordered membrane domains extracted from either in-
fected cells or infected mouse brain [8–11]. Furthermore, Baron
et al. proved that these ordered membrane domains (rafts) act as
a ‘‘meeting place’’ between PrPC and PrPSc. Conversion only occursbranes [2]. Recently, Goold et al. developed a new cell-based sys-
tem in which epitope-tagged PrPC is expressed in a wt-PrP-
knockdown neuronal cell line. This cell line was exposed to RML
prion and it was found that the formation of de novo epitope-
tagged PrPSc primarily occurred on the plasma membrane within
ordered membrane domains [3].
Even though there is conclusive evidence demonstrating the
inﬂuence of membrane attachment of PrP via its GPI anchor on
the conversion process available, most in vitro studies still use re-
combinant PrP without a membrane anchor [12–17] or heteroge-
neous posttranslationally modiﬁed PrPC extracted from neuronal
cells [2,18]. In order to generate membrane attached PrP variants,
we have previously developed semisynthetic strategies to create
homogeneous lipidated PrPC by combining recombinant protein
technology and chemically synthesized GPI mimics [6,7,19]. These
strategies rely on expression of PrP in fusion with an Mxe intein in
Escherichia coli in order to generate PrP with a C-terminal a-thioes-
ter group, which is required for expressed protein ligation (EPL)
with membrane anchors, or on the use of the DnaE split intein.
However, these constructs are typically deposited in inclusion
bodies in E. coli, probably due to the structurally important disul-
ﬁde bridge in PrP [20]. Generation of PrP a-thioesters require sol-
ubilizing these inclusion bodies under denaturing conditions,
which severely limits the yield of the intein cleavage and subse-
quent EPL reactions.
In order to improve semisynthetic access to posttranslationally
modiﬁed PrP, we have set out to develop soluble expression of
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uble, folded PrP will allow more straightforward access to homoge-
neously modiﬁed PrP variants, e.g. carrying a C-terminal
membrane anchor and/or N-glycosylations. Efforts to achieve this
goal by co-expression of PrP with bacterial chaperones in the cyto-
plasm of E. coli in order to assist the folding of prion protein failed
[21].
However, previous experiments by others have shown that a di-
rect N-terminal fusion of E. coli DnaK chaperone leads to an im-
proved solubility of recombinantly expressed proteins in E. coli
[21]. Therefore we cloned, expressed and tested a variety of N-ter-
minal fusion constructs with PrP-Mxe intein constructs.
2. Materials and methods
2.1. Materials
All chemicals used were purchased from Sigma–Aldrich, Roche
and Merck-Chemicals in the highest purity available if not other-
wise stated. The Sortase A expression plasmid pET30b-SrtA is a
kind gift from Professor Teruyuki Nagamune [22].
2.2. Plasmid construction
Plasmid pTXB3-PrP containing a mouse PrP(90–231)-encoding
gene [6] was used as template for cloning work. The E. coli K12
DnaK-encoding gene was N-terminally fused to a gene coding for
PrP(90–231) to give plasmid pET30-HDP. The DnaK-substrate
binding domain was removed from pET30-HDP and a TEV cleavage
site replaced with a SrtA-site in pET30-ASP plasmid. This plasmid
was extended by a C-terminal fusion to give an intein fusion con-
struct in plasmid pET30-ASPM (for details see Supplementary
material).
2.3. Protein expression and puriﬁcation
All protein constructs are expressed in 2xYT medium after IPTG
induction at 25 C overnight (for details see Supplementary mate-
rial). Puriﬁcation of all constructs was carried out as described for
6xHis-DnaK (Supplementary material).
2.4. Protease cleavage reactions
Puriﬁed HDP protein was cleaved by TEV protease as previously
described [23]. Here we used a ratio of HDP and TEV of 30:1 (w:w)
in 50 mM Tris–HCl, pH 8.0, 0.5 mM EDTA, 2 mM PMSF and 3 mM/
0.3 mM GSH/GSSG, and incubated at 10 C overnight. Sortase A
cleavages were carried out in 50 mM Tris–HCl, pH 8.0 buffer con-
taining 5 mM CaCl2, 10 mM Gly–Gly–Gly (Sigma) and 2 mM PMSF
at room temperature, overnight (Supplementary material).
2.5. Circular dichroism (CD) spectroscopy
Far-UV CD spectra were recorded at 22 C on an Applied Photo-
physics Chirascan Plus system. PrP proteins were diluted in 20 mM
NaOAc at pH 5.5 to a ﬁnal concentration of 12 lM. CD spectra were
collected at a scan speed of 20 nm/min at 1 nm bandwidth and re-
sponse time of 4 s. All spectra were recorded in a 0.1 cm cuvette
between 195 and 260 nm. All data shown here represent the aver-
age of 10 recorded spectra.
2.6. Preparation of ASP containing a C-terminal a-thioester
Puriﬁed ASPM protein was immobilized on chitin beads and
cleaved by addition of 250 mM sodium 2-mercaptoethanesulfo-nate (MESNA) in 50 mM Tris–HCl, pH 8.0 at 4 C overnight. The
resulting ASP containing C-terminal a-thioester (ASP-SR) found
in the ﬂow through of the cleavage reaction was submitted to a
Superdex 75 (16/60) column equilibrated with 50 mM Tris–HCl
buffer at a ﬂow rate of 0.5 ml/min. Pure fractions of ASP-SR were
pooled and concentrated by using ultraﬁltration (Amicon 30KDa
MWCO, Millipore).
2.7. Expressed protein ligation
Expressed protein ligation (EPL) was carried out in 50 mM Tris–
HCl, pH 8.0, 2% (v/v) ethanethiol with concentrations of 50 lM
ASP-SR and 500 lM NBD peptide at room temperature for 24 h.
Reactions were analyzed by SDS–PAGE followed by ﬂuorescence
scanning and coomassie staining. Reaction mixtures were dialyzed
against 50 mM Tris–HCl, pH 8.0 buffer and Sortase A was added.
3. Results and discussion
3.1. Construction of DnaK-PrP fusion protein, expression and
puriﬁcation
The plasmid expressing E. coli DnaK with an N-terminal 6xHis
tag (Fig. 1) was constructed as described above. The resulting plas-
mid (pET30-DnaK) is transcribed under control of an IPTG induc-
ible T7 promoter. Expression and puriﬁcation of this His-DnaK
construct provided 14 mg of His-DnaK from 1 l medium in 3 h after
induction (Fig. S1A). Subsequently, the mouse PrP(90–231) encod-
ing gene was cloned into pET30-DnaK to form plasmid pET30-HDP.
Expression of the resulting His-DnaK-PrP (HDP) construct was
evaluated by SDS–PAGE. IPTG-induced overexpression of HDP pro-
vides the target protein mainly in the soluble fraction (Fig. 2A)
which is in good agreement with a similar strategy previously ap-
plied for soluble expression of full-length PrP [21]. HDP protein
was puriﬁed by Ni–NTA afﬁnity chromatography followed by size
exclusion chromatography (SEC) using a Superdex 200 (16/60) col-
umn to achieve high purity in combination with an excellent over-
all yield of 42 mg HDP from 1 l of E. coli culture (overnight
expression, Fig. 2B).
3.2. Cleavage of DnaK from DnaK-PrP
Puriﬁed HDP protein was cleaved by addition of recombinantly
expressed TEV protease (see Supplementary material). Favorable
redox conditions for this cleavage reaction as well as for maintain-
ing the crucial internal disulﬁde bridge in PrP were achieved by
addition of the redox couple GSH/GSSG. Protease cleavage was
monitored by SDS–PAGE and was complete after overnight incuba-
tion at 10 C. Even though control of the redox conditions helped to
stabilize PrP, a subsequent centrifugation step was required to re-
move precipitated PrP. Approximately 10% of PrP precipitated un-
der these conditions. Separation of the remaining soluble PrP from
the DnaK-tag and from TEV protease was expected to work via Ni–
NTA afﬁnity puriﬁcation. PrP should be collected in the ﬂow-
through while DnaK and TEV should bind to the Ni–NTA matrix
via their respective His-tags. However, this strategy for separating
PrP from DnaK was unsuccessful in our hands. Only minor amounts
of soluble PrP were found in the ﬂow-through and the majority of
PrP eluted together with DnaK at concentration of 250 mM imidaz-
ole (Fig. 2C). This behavior can be explained by a rather strong
interaction between the substrate binding domain (SBD) of DnaK
with PrP as observed in other cases [24,25]. Based on this assump-
tion we removed the DnaK-SBD and speculated that the ATPase do-
main by itself would impart similar solubilizing properties as the
complete DnaK protein.
Fig. 1. (A) Scheme of all generated fusion proteins. (B) NcoI site in DnaK. (C) Semisynthesis strategy to create soluble PrP with C-terminal modiﬁcations.
Fig. 2. SDS–PAGE analysis of soluble DnaK-PrP fusion protein (HDP). (A) Expression, M: mfolecular weight marker; T: total cell extract, S: soluble fraction, P: pellet fraction.
(B) Puriﬁcation of HDP, 0: Ni–NTA eluate, 1: pure fraction from SEC. (C) TEV cleavage, T: total reaction mix, FT: ﬂow through, E: elution after incubation with Ni–NTA resin.
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To this end we could take advantage of a natural NcoI site ide-
ally positioned just at the beginning of the SDB within the DnaK
gene (Fig. 1B). Moreover, we replaced the TEV protease cleavage
site with a Sortase A (SrtA) site to circumvent the use of reducing
agents during TEV cleavage reactions, which causes partial precip-
itation of PrP as described above. These changes led to the ATPase-
SrtA-PrP (ASP) construct, which was tested for soluble expression
in two E. coli strains: BL21(DE3)RIL and Origami 2 (DE3) RIL. The
latter one has been described as an E. coli strain that greatly en-
hances disulﬁde bridge formation in the cytoplasm [26]. Here, we
did not recognize any signiﬁcant differences in solubility and
expression levels between both strains (Fig. 3A). Based on this
comparison we conclude that the ATPase domain of DnaK in the
ASP construct is sufﬁcient to ensure soluble overexpression in
the cytoplasm of E. coli.
Puriﬁcation was now achieved by Ni–NTA afﬁnity chromatogra-
phy as described above and provided highly pure ASP protein withan average yield of 85 mg/l culture (Fig. 3B). This ﬁnding conﬁrms
our initial assumption that the SBD of DnaK mediates tight binding
to PrP but plays only a minor role in solubilizing it. Cleavage of
puriﬁed ASP protein by SrtA was optimized by screening several
conditions (Fig. S2A). Optimized conditions resulted in quantitative
release of soluble PrP from the ASP construct (Fig. S2B). The iden-
tity of PrP was conﬁrmed by western blot analysis (Fig. S1B).
3.4. High yield production of soluble PrP(90–231) from ASP construct
Optimal conditions for expression, cleavage and puriﬁcation of
soluble PrP as identiﬁed above were applied for processing 85 mg
of pure ASP obtained from 1 l of E. coli culture to produce soluble
PrP. Only minor amounts of PrP are retained on the Ni–NTA matrix
via unspeciﬁc interaction (Fig. 3C). Removal of the SBD almost
completely alleviates the problem of PrP not eluting from to the
Ni–NTA matrix.
Next, the secondary structure of soluble PrP was analyzed by CD
spectroscopy and compared to recombinant PrP that was refolded
Fig. 3. SDS–PAGE analysis of ATPase-PrP fusion protein (ASP). (A) Soluble expression in two E. coli strains: BL21(DE3)RIL and Origami2(DE3)RIL, N: control without IPTG, T:
total cell extract, S: soluble fraction of lysed cells. (B) Puriﬁcation of ASP, 0: Ni–NTA eluate, 1: pure fraction from SEC. (C) SrtA cleavage, 1: total reaction mix, 2: ﬂow through,
and 3: elution from Ni–NTA resin. (D) CD spectra of soluble PrP from ASP construct (circles) and refolded PrP protein (triangles) from inclusion bodies.
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variants showed similar CD spectra with 2 minima at 208 and
222 nm indicating predominantly a-helical proteins (Fig. 3D).
Quantitative analysis indicates a similar percentage of a-helical
structure elements in both PrP variants, typical for cellular PrPC
protein [27,28]. The overall yield of soluble PrP protein from this
strategy was 15 mg from 1 l of E. coli culture (69% based on the
amount of total PrP expressed), indicating the superior results ob-
tained with this strategy when compared to another recently pub-
lished soluble expression system for PrP [29]. Furthermore, an
aggregation experiment, based on Thioﬂavin T binding of ﬁbrils,
for soluble, refolded and denatured PrP variants was conducted
to compare their biochemical characteristics. Soluble and refolded
PrP exhibit a similar ﬁbrillation behavior with an extended lag
phase between 30 and 40 h, very different from that of denatured
PrP with a lag-phase of ca. 10 h (Fig. S4). In combination with the
secondary structure analysis this experiment emphasizes the sim-
ilar properties of soluble and refolded PrP.
3.5. Preparation of soluble PrP containing a C-terminal a-thioester
The successful strategy for expression of large amounts of solu-
ble PrP(90–231) was extended to soluble expression of a PrP-intein
construct. To this end we added a C-terminalMxe mini-intein-CBD
tag to ASP. Soluble expression of this ASPM construct in E. coli
BL21(DE3)RIL was conﬁrmed by analysis of centrifugation fractions
of lysed cells. ASPM accumulated mostly in the supernatant
(Fig. 4A). Ni–NTA puriﬁcation yielded ASPM that was subsequentlyimmobilized on chitin beads via its C-terminal CBD (Fig. 4B). PrP
expression was also conﬁrmed by western blot analysis
(Fig. S1B). Addition of 250 mM MESNA led to cleavage of the Mxe
mini-intein and to spontaneous formation of an a-thioester group
at the C-terminus of the ASP protein. The resulting ASP-SR was
found in the supernatant (Fig. 4C) and further puriﬁed by SEC using
a Superdex 75 (16/60) column to reach high purity (Fig. 4D). The
presence of an a-thioester group at the C-terminus of ASP was con-
ﬁrmed by successful expressed protein ligation (EPL) with a ﬂuo-
rescently labeled peptide (NBD-peptide, analytical data in Fig. S3)
containing an N-terminal cysteine residue (Fig. 1C) [30]. SDS–PAGE
analysis in combination with a ﬂuorescence scan of the gel prior to
coomassie staining clearly proved that the ASP protein is almost
quantitatively linked to the NBD peptide (Fig. 4E). In a ﬁnal step,
the EPL reaction mix was incubated with SrtA in order to release
soluble PrP carrying the NBD peptide. After incubation for 16 h
the reaction mix was centrifuged and the supernatant was again
analyzed by SDS–PAGE (Fig. 4F). Almost quantitative ligation and
subsequent complete removal of the ATPase domain make this
strategy much more efﬁcient than previously used systems based
on refolded PrP and even split inteins [6].
To study the efﬁciency of the above described reaction in re-
verse order (Fig. 1C), 4 mg of ASPM protein were immobilized on
2 ml of chitin beads and the ATPase domain was cleaved off by SrtA
to produce PrP-intein on chitin beads (Fig. 5A). Immobilized PrP-
intein was mixed with 100 lM NBD peptide (Fig. S3) and 50 mM
MESNA in buffer containing 50 mM Tris–HCl at pH 8.0, 1 mM EDTA
and 0.5 mM TCEP. The in situ cleavage and ligation reaction was
Fig. 5. C-terminal modiﬁcation of soluble PrP. (A) SDS–PAGE of SrtA cleavage of immobilized ASPM protein. 1: ASPM used for loading chitin beats, 2: excess ASPM not bound
to beads, 3: ASPM immobilized on chitin beads, 4: SrtA addition leads to release of ATPase domain, 5: PrP-intein bound to chitin beads. (B) SDS–PAGE analysis of soluble PrP-
NBD generated by in situ cleavage and EPL reaction with NBD peptide and subsequent puriﬁcation by Ni–NTA chromatography. Coomassie staining (a) and ﬂuorescence scan
(b); (C) CD spectrum of PrP-NBD; (D) ESI-MS of soluble PrP-NBD.
Fig. 4. SDS–PAGE analysis of ASPM and ASP-SR in EPL reactions. (A) ASPM expression, T: total cell extract, S: soluble fraction, P: pellet fraction of lysed cells. (B) 1: Ni–NTA
puriﬁcations of ASPM, 2: ASPM immobilized on chitin beads, 3: ﬂow through. (C) MESNA-induced cleavage of ASPM, 1: ASPM protein, 2: ASP-SR released from chitin beads.
(D) ASP-SR puriﬁcation by SEC, 0: crude ASP-SR, 1: pure fraction. (E) EPL reaction of ASP-SR with NBD peptide; (a) coomassie staining, (b) ﬂuorescence scan. (F) ASP-NBD after
SrtA cleavage; (a) coomassie staining and (b) ﬂuorescence scan.
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the ligation product PrP-NBD was centrifuged to remove chitinbeads, dialyzed against buffer (50 mM Tris–HCl, pH 8.0) to remove
excess NBD peptide and loaded on Ni–NTA resin to obtain puriﬁed
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was obtained with an overall yield of 250 lg from 4 mg of ASPM
protein (32% based on the total amount of PrP that can theoreti-
cally be obtained from ASPM protein). Next, the secondary struc-
ture of soluble PrP-NBD was analyzed by CD spectroscopy, which
showed the typical a-helical features of correctly folded cellular
PrP (Fig. 5C). ESI-MS analysis of PrP-NBD protein gave a molar mass
of 17739 Da (Fig. 5D), which deviates by +71 Da from the calcu-
lated mass of 17668 Da. Such a difference was observed only when
TCEP was added to the in situ cleavage and ligation reaction over
extended periods of time at a concentration of 0.5 mM to prevent
oxidation of the N-terminal cysteine residue of the NBD peptide.
TCEP has long been recognized as a well-tolerated and widely used
reducing agent that does not cause signiﬁcant side reactions under
many conditions [31]. However, here at pH 8.0 TCEP or an unde-
tectable by product causes a deﬁned modiﬁcation of the PrP, which
does not occur in the absence of TCEP.
4. Conclusion
We developed the soluble expression of a recombinant PrP-Mxe
intein fusion protein (ASPM) to improve the efﬁciency of semisyn-
thetic strategies for producing homogenously posttranslationally
modiﬁed PrP. We showed that PrP-Mxe intein protein N-terminally
fused to the ATPase domain of HSP 70 DnaK overexpresses as a sol-
uble protein in the cytoplasm of E. coli. Consequently, this fusion
allows a straightforward way to generate PrP-variants containing
C-terminal modiﬁcations without the need for subsequent protein
folding and disulﬁde bond formation. The latter step can be espe-
cially challenging when introducing additional cysteine residues,
e.g. during EPL reactions that increase the probability of non-native
disulﬁde bond formation. We further improved this strategy of sol-
uble expression by minimizing the DnaK fusion partner down to
the ATPase domain alone. This leads to high quantities of soluble,
cellular PrP even in the presence of a C-terminal intein fusion as
well as preventing undesired strong interactions between the
DnaK-SBD and PrP. Previous studies reported that neither co-
expression with chaperones nor periplasmic expression in E. coli
succeeded in producing soluble intact PrP proteins [21,32]. Thus,
we believe that this strategy can be extensively applied for soluble
expression of other proteins containing disulﬁde bridges in fusion
with intein for semisynthesis method.
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